scanance.
Sign inGet Premium
VR

VERAXA Biotech AG

VRXAHealthcareNASDAQ

Biotechnology · Last scanned Jun 15, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$0
Net Income
-$28.1M
-70.0% YoY
EBITDA
-$26.9M
-70.1% YoY

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About VERAXA Biotech AG

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. With a market capitalization of $2.73B, it sits in mid-cap territory. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.

Key stats
Market Cap$2.73B
EPS$-0.50
52W Change+92.7%
Analysis

As with any equity investment, VRXA carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VRXA.

Links
⚠Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms
VRXA — VERAXA Biotech AG Technical Analysis | Scanance